This summary explains the findings from a recent investigation that combined the results of over 1000 people from three clinical studies to understand the safety of evobrutinib.Evobrutinib is an oral medication (taken by mouth), being researched as a potential treatment for multiple sclerosis (MS). This medication was also investigated in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).Over 1000 people have taken evobrutinib as part of three separate phase 2 clinical studies. These studies looked at how much of the drug should be taken, how safe the drug is, and how well it might work for treating a certain medical condition.This Plain Language Summary of Publication from Neurodegenerative Disease Management summarises the findings from three studies which looked at the safety of the medication evobrutinib. The research shows encouraging results that can inform further research into using the medication to treat multiple sclerosis.

Read the full article here.

This summary is based on an original article published in the Journal of Neurology, Neurosurgery & Psychiatry. The original article is called ‘Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis’. You can read it here.